natgillin/translations-raw huggingface dataset:
Mentale forstyrrelser, selvmordsforsøg, angst, konfusion, forsænket stemningsleje, major depression, afbrudt søvnmønster, ændret stemningsleje, panikanfald, søvnforstyrrelser, suicidale tanker, suicidal adfærd (især hos patienter med psykisk sygdom i anamnesen)
mental disorder, suicide attempt, anxiety, confusional state, depressed mood, major depression, middle insomnia, mood altered, panic attack, sleep disorder, suicidal ideation, suicidal behaviour (particularly in patients with a pre-existing history of psychiatric illness)
Menveo anvendes til beskyttelse af voksne, unge og børn fra 2 årsalderen mod invasiv meningokok- sygdom forårsaget af fire grupper af bakterien N. meningitidis (A, C, W-135 og Y).
Menveo is used to protect adults and children from the age of two against invasive disease caused by four groups of the bacterium N. meningitidis (A, C, W135, and Y).
Menveo er en vaccine, der benyttes til aktiv beskyttelse af børn (fra 2 år), unge og voksne med risiko for at blive udsat for en bakterie, der kaldes Neisseria meningitidis, serogruppe A, C, W135 og Y, som forebyggelse mod sygdom.
Menveo is a vaccine that is used for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to a bacterium named Neisseria meningitidis serogroups A, C, W135 and Y, to prevent invasive disease.
Menveo er et pulver og et solvens til injektion.
Menveo is a powder and a solution for injection.
Menveo er indiceret til aktiv immunisering af børn (fra 2 år), unge og voksne med risiko for eksponering for Neisseria meningitidis-gruppe A, C, W135 og Y til forebyggelse af invasiv sygdom.
Menveo is indicated for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.
Menveo hSBA ≥ 1:8 (95 % CI)
Menveo hSBA ≥ 1:8 (95% CI)
Menveo kan gives samtidigt med en hvilken som helst af følgende vacciner: monovalent og kombineret hepatitis A og B, gul feber, tyfus (Vi polysaccharid), japansk encefalitis og rabies.
Menveo can be given concomitantly with any of the following vaccines: monovalent and combined hepatitis A and B, yellow fever, typhoid fever (Vi polysaccharide), Japanese encephalitis and rabies.
Menveo opløsning til injektion MenCWY konjugat Intramuskulær anvendelse
Menveo solution for injection MenCWY Conjugate Intramuscular use
Menveo pulver og solvens til injektionsvæske, opløsning
Menveo powder and solution for solution for injection
Menveo pulver og solvens til injektionsvæske, opløsning Meningokokgruppe A, C, W135 og Y konjugat vaccine
Menveo powder and solution for solution for injection Meningococcal Group A, C, W135 and Y conjugate vaccine
Menveo pulver og solvens til injektionsvæske, opløsning Meningokokgruppe A, C, W135 og Y konjugeret vaccine
Menveo powder and solution for solution for injection Meningococcal Group A, C, W135 and Y conjugate vaccine
Menveo pulver til injektion MenA konjugat Intramuskulær anvendelse
Menveo powder for injection MenA Conjugate Intramuscular use
Menveo skal gives som en enkeltdosis på 0,5 ml.
Menveo should be administered as a single dose (0.5 ml).
Menveo skal klargøres til administration ved at rekonstituere pulveret (i hætteglas) med solvens (i hætteglas).
Menveo must be prepared for administration by reconstituting powder (in vial) with solution (in vial).
Menveo var non-inferiore i forhold til ACWY-PS vaccine for alle fire serogrupper (A, C, W135 og Y) baseret på serorespons, andele der opnåede hSBA ≥ 1:8, og GMT.
Menveo was shown to be non-inferior to ACWY-PS vaccine for all four serogroups (A, C, W135 and Y) based on seroresponse, proportions achieving hSBA ≥1:8, and GMTs.
MEPACT er et hvidt eller off-white ensartet pulver til koncentrat til infusionsvæske, dispersion.
MEPACT is a white to off-white homogeneous cake or powder for concentrate for dispersion for infusion.
MEPACT er indiceret til børn, unge under 18 år og unge voksne til behandling af resektabel ikke- metastatisk osteosarkom med høj malignitetsgrad efter makroskopisk komplet kirurgisk resektion.
MEPACT is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection.
MEPACT leveres i en pakning, der indeholder
MEPACT is supplied in a carton that contains
MEPACT pulver til koncentrat til infusionsvæske, dispersion (hætteglas)
MEPACT powder for concentrate for dispersion for infusion (vial)
MEPACT skal rekonstitueres, filtreres gennem det medfølgende filter og fortyndes yderligere, før det indgives.
MEPACT must be reconstituted, filtered using the filter provided and further diluted prior to administration.
MEPACT skal under aseptiske forhold opløses, filtreres gennem det medfølgende filter og fortyndes yderligere.
MEPACT must be reconstituted, filtered using the filter provided and further diluted using aseptic technique.
MEPACT-dosen er 2 mg mifamurtid/m2 legemsoverfladeareal.
The dose of MEPACT is 2 mg mifamurtide/m2 body surface area.
Meperidin
Close clinical
Mepolizumab 100 mg (subkutant)
Mepolizumab 100 mg (subcutaneous)
Mepolizumab bindes til stoffet interleukin- 5, der øger produktion og overlevelse af eosinofile.
Mepolizumab attaches to a substance called interleukin-5 which encourages the production and survival of eosinophils.
Mepolizumab hæmmer bioaktiviteten af IL-5 med nanomolær styrke ved at blokere bindingen af IL-5 til alfa-kæden i IL-5- receptorkomplekset, der er udtrykt på overfladen af eosinofile celler, hvorved den IL-5-inducerede signalering hæmmes, og produktionen og overlevelsen af de eosinofile celler nedsættes.
Mepolizumab inhibits the bioactivity of IL-5 with nanomolar potency by blocking the binding of IL-5 to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface, thereby inhibiting IL-5 signalling and reducing the production and survival of eosinophils.
Mercaptopurin (anvendes til behandling af kræft)
Mercaptopurine (used to treat cancer)
Mercaptopurins indvirkning på andre lægemidler
Effects of mercaptopurine on other medicinal products
Merck Hepatitis B (rekombinant) vaccine
Merck Hepatitis B (Recombinant) Vaccine
Merck KGaA 64271 Darmstadt Tyskland
Merck KGaA 64271 Darmstadt Germany
Merck KGaA, Frankfurter Straße 250 D-64293 Darmstadt Tyskland
Merck KGaA, Frankfurter Straße 250 D-64293 Darmstadt Germany
Merck KGaA, Frankfurter Straße 250, D-64293 Darmstadt, Tyskland
Merck KGaA, Frankfurter Straße 250, D-64293 Darmstadt, Germany
Merck Serono Europe Limited
Merck Serono Europe Limited 56, Marsh Wall
Merck Serono Europe Limited, 56 Marsh Wall
Merck Serono Europe Limited 56 Marsh Wall
Merck Serono Europe Limited, 56 Marsh Wall, London E14 9TP, Storbritannien
Merck Serono Europe Limited, 56 Marsh Wall, London E14 9TP, United Kingdom
Merck Serono Europe Limited, 56 Marsh Wall, London E14 9TP, Storbritannien
Merck Serono Europe Limited, 56 Marsh Wall, London E14 9TP, United Kingdom.
Merck Serono Europe Limited, 56 Marsh Wall, London E14 9TP, Storbritannien.
Merck Serono Europe Limited, 56 Marsh Wall, London E14 9TP, United Kingdom
Merck Serono Europe Limited, 56, Marsh Wall, London E14 9TP Storbritannien
Merck Serono Europe Limited, 56 Marsh Wall, London E14 9TP, United Kingdom
Merck Serono S.A. – Corsier-sur-Vevey Route de Fenil – Z.I.B.,
Merck Serono S.A. – Corsier-sur-Vevey Route de Fenil – Z.I.B.
Merck Serono S.p.A, Via delle Magnolie 15 (Zona industriale), I-70026 Modugno (Bari), Italien
Merck Serono S.p.A, Via delle Magnolie 15 (Zona industriale), I-70026 Modugno (Bari), Italy
Merck Serono S.p.A. Via delle Magnolie 15 70026 Modugno (Bari) Italien
Merck Serono S.p.A. Via delle Magnolie 15 70026 Modugno (Bari) Italy
Merck Serono S.p.A., Via delle Magnolie 15, 70026 Modugno (Bari) Italien
Merck Serono S.p.A., Via delle Magnolie 15, 70026 Modugno (Bari), Italy
Merck Sharp & Dohme (Italien) S.p.A. Via Emilia 21
Merck Sharp & Dohme (Italia) S.p.A. Via Emilia 21
Merck Sharp & Dohme (Sweden) AB Tel: + 46 77 570 04 88 medicinskinfo@merck.com
Merck Sharp & Dohme (Sweden) AB Tel: + 46 77 5700488 medicinskinfo@merck.com
Merck Sharp & Dohme (Sweden) AB Tel: +46 (0)77 5700488 medicalinformationuk@merck.com
Merck Sharp & Dohme (Sweden) AB Tel: +46 (0)77 5700488 medicinskinfo@merck.com
Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 medicinskinfo@merck.com
SIA Merck Sharp & Dohme Latvija Tel: +371 67364224 msd_lv@merck.com
Merck Sharp & Dohme (Sweden) AB Tel: +46 77 57004888 medicinskinfo@merck.com
Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 medicinskinfo@merck.com
Merck Sharp & Dohme Animal health, S.L. Poligono El Montalvo I
Merck Sharp & Dohme Animal Health, S.L. Poligono Ind. El Montalvo I
Merck Sharp & Dohme B.V Waarderweg 39
Merck Sharp & Dohme B. V. Waarderweg 39
Merck Sharp & Dohme B.V.
Merck Sharp & Dohme BV
Merck Sharp & Dohme B.V., Waarderweg 39, P.O. Box 581, 2003 PC Haarlem, Holland
Merck Sharp & Dohme B.V., Waarderweg 39, P.O. Box 581, 2003 PC Haarlem, The Netherlands
Merck Sharp & Dohme BV, Waarderweg 39, 2031 BN Haarlem, Holland eller
Merck Sharp & Dohme BV, Waarderweg 39, 2031 BN Haarlem, The Netherlands or
Merck Sharp & Dohme Cyprus Limited Tel.: 8007 4433 (+356 99917558) malta_info@merck.com
Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com
Merck Sharp & Dohme Cyprus Limited Tel.: 8007 4433 (+35699917558) malta_info@merck.com
Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com
Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com
Merck Sharp & Dohme Cyprus Limited Tel: +8007 4433 (+356 99917558) malta_info@merck.com
Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com Associated Drug Co.
Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com
Merck Sharp & Dohme Cyprus Limited Τel: 8007 4433 (+356 99917558)
Τel: 8007 4433 (+356 99917558)
Merck Sharp & Dohme Cyprus Limited Τηλ.: 800 00 673 (+357 22866700) cyprus_info@merck.com
Merck Sharp & Dohme Cyprus Limited Τηλ: 80000 673 (+357 22866700) cyprus_info@merck.com
Merck Sharp & Dohme Cyprus Limited Τηλ: +80000 673 (+357 22866700)
Merck Sharp & Dohme Romania S.R.L. Tel: + 4021 529 29 00
Merck Sharp & Dohme Cyprus Limited, Tlf: 8007 4433 (+356 99917558)
Merck Sharp & Dohme Cyprus Limited, Tel: 8007 4433 (+356 99917558)
Merck Sharp & Dohme Cyprus Limited., Tel: 8007 4433 (+356 99917558)
MSD Pharma Hungary Kft., Tel.: + 36.1.888.5300
Merck Sharp & Dohme d.o.o., Tel: +385 1 66 11
Merck Sharp & Dohme d.o.o., Tel: +385 1 66 11 333
Merck Sharp & Dohme d.o.o., Tlf: +385 1 66 11
Merck Sharp & Dohme d.o.o., Tel: +385 1 66 11
Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 msd.info@merck.com
Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 msd_info@merck.com
Merck Sharp & Dohme Ges..m.b.H.
Merck Sharp & Dohme Ges.m.b.H.
Merck Sharp & Dohme Ireland (Human Health) Lim- ited
Merck Sharp & Dohme Ireland (Human Health) Limited
Merck Sharp & Dohme Limited
Merck Sharp & Dohme Ltd
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN 11 9BU Storbritannien
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU Storbritannien
Merck Sharp &Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertforshire EN11 9BU Storbritannien
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Merck Sharp & Dohme Limited Laboratoires Merck Sharp & Dohme - Chibret Hertford Road, Hoddesdon Route de Marsat - Riom
Merck Sharp & Dohme Limited Laboratoires Merck Sharp & Dohme – Chibret Hertford Road, Hoddesdon Route de Marsat - Riom
Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 medicalinformationuk@merck.co
Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 medicalinformationuk@merck.com
Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 medicalinformationuk@merck.com
Merck Sharp & Dohme Limited Tel: + 44 (0) 1992 467272 medicalinformationuk@merck.com
Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 medinfo_uk@merck.com
Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 medicalinformationuk@merck.com
Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, Storbritannien
Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom
Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, Storbritannien
Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom.
Merck Sharp & Dohme Ltd.
Merck Sharp & Dohme Limited Merck Sharp & Dohme B. V.
Merck Sharp & Dohme OÜ Tel.: +372 6144 200 msdeesti@merck.com
Merck Sharp & Dohme OÜ Tel: +372 6144 200 msdeesti@merck.com
Merck Sharp & Dohme OÜ Tel: +372 6144200 msdeesti@merck.com
Merck Sharp & Dohme OÜ Tel.: +372 6144 200 msdeesti@merck.com
Merck Sharp & Dohme OÜ, Tel: +372.6144200
Merck Sharp & Dohme OÜ, Tel: +372.
Merck Sharp & Dohme OÜ, Tlf: +372 6144 200
Merck Sharp & Dohme OÜ, Tel: +372 6144 200
Merck Sharp & Dohme Romania S.R.L. Tel. +40 21 529 290 msdromania@merck.com
Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 msdromania@merck.com
Merck Sharp & Dohme Romania S.R.L. Tel.: + 4021 529 29 00 msdromania@merck.com
Merck Sharp & Dohme Romania S.R.L. Tel: + 4021 529 29 00 msdromania@merck.com
Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 2900 msdromania@merck.com
Merck Sharp & Dohme Romania S.R.L. Tel: + 4021 529 29 00 msdromania@merck.com
Merck Sharp & Dohme Romania S.R.L., Tlf: +4 021 529 29 00
Merck Sharp & Dohme Romania S.R.L., Tel: +4 021 529 29 00
Merck Sharp & Dohme s. r. o.
Merck Sharp & Dohme, s. r. o., Tel:
Merck Sharp & Dohme s. r. o., Tlf:
Merck Sharp & Dohme s. r. o., Tel:
Merck Sharp & Dohme, inovativna zdravila d.o.o., Tel: +386.1.520.4201
Merck Sharp & Dohme Cyprus Limited
Merck Sharp & Dohme, inovativna zdravila d.o.o., Tlf: +386 1 5204 201
Merck Sharp & Dohme, inovativna zdravila d.o.o., Tel: +386 1 5204 201
Merck Sharp & Dohme, s.r.o.
Merck Sharp & Dohme, s. r. o.
Merck Sharp and Dohme B.V., Waarderweg 39, 2031 BN Haarlem, Holland
Merck Sharp and Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
Merck Sharp and Dohme B.V.Waarderweg, 39
Merck Sharp and Dohme B.V. Waarderweg, 39
Merck Sharp and Dohme Ireland (Human Health) Limited
Merck Sharp & Dohme Ireland (Human Health) Limited
Merck Sharp and Dohme Limited Tel: +44 (0) 1992 467272 medicalinformationuk@merck.com
Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 medicalinformationuk@merck.com
Merck Sharp and Dohme, B.V.Waarderweg, 39
Merck Sharp and Dohme B.V. Waarderweg, 39
Merck, Sharp & Dohme Ltd SP Labo NV
Merck Sharp & Dohme Ltd S-P Labo NV
Mere almindeligt rapporteret, når tadalafil gives til patienter, som allerede tager antihypertensiva.
More commonly reported when tadalafil is given to patients who are already taking antihypertensive medicinal products.
Mere alvorlige bivirkninger er lungebetændelse og knoglebrud (optræder hos 1 ud af 10 behandlede), som oftere blev indberettet for patienter med KOL end for patienter med astma.
More serious side effects include pneumonia and fractures (seen in up to 1 in 10 people), which were reported more often in patients with COPD than those with asthma.
Mere alvorlige overfølsomhedsreaktioner inklusive angioødem, dyspnø/bronkospasme og anafylaktisk chok.
More severe hypersensitivity reactions including angioedema, dyspnoea/ bronchospasm and anaphylactic shock.
mere blødning end normalt efter skader,
more bleeding than usual after injury,
Mere end 1 hætteglas Nivolumab BMS-koncentrat kan være nødvendigt for at kunne give patienten den totale dosis.
More than one vial of Nivolumab BMS concentrate may be needed to give the total dose for the patient.
Mere end 1 hætteglas OPDIVO koncentrat kan være nødvendigt for at kunne give patienten den totale dosis.
More than one vial of OPDIVO concentrate may be needed to give the total dose for the patient.
Mere end 1 hætteglas OPDIVO-koncentrat kan være nødvendigt for at kunne give patienten den totale dosis.
More than one vial of OPDIVO concentrate may be needed to give the total dose for the patient.
Mere end 12 timer efter planlagt administration: patienten skal tage næste dosis som planlagt og ikke tage dobbelt dosis
For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose.
Mere end 15 kg og op til 23 kg
More than 15 kg and up to 23 kg
Mere end 15 kg og op til 23 kg
More than 15 kg, up to 23 kg
Mere end 15.000 patienter med type 2-diabetes deltog i dobbeltblindede, placebo- eller aktivkontrollerede kliniske forsøg af op til over 2 års varighed.
More than 15,000 patients with type 2 diabetes participated in double-blind placebo- or active- controlled clinical trials of up to more than 2 years’ treatment duration.
Mere end 23 kg og op til 40 kg
More than 23 kg and up to 40 kg
Mere end 23 kg og op til 40 kg
More than 23 kg, up to 40 kg
Mere end 3.000 patienter er blevet behandlet med nalmefen i kliniske undersøgelser.
More than 3,000 patients have been exposed to nalmefene in clinical studies.
Mere end 3.900 hypertensive patienter har fået Rasilez HCT en gang dagligt i kliniske studier.
Over 3,900 hypertensive patients received Rasilez HCT once daily in clinical trials.
Mere end 3.900 hypertensive patienter har fået Riprazo HCT en gang dagligt i kliniske forsøg.
Over 3,900 hypertensive patients received Riprazo HCT once daily in clinical trials.
Mere end 3.900 hypertensive patienter har fået Sprimeo HCT en gang dagligt i kliniske forsøg.
Over 3,900 hypertensive patients received Sprimeo HCT once daily in clinical trials.
Mere end 37.816 spædbørn blev immuniseret med enten Prevenar eller en kontrolvaccine (konjugeret meningokok gruppe C vaccine) i en alder af 2, 4, 6 og 12-15 måneder.
More than 37,816 infants were immunised with either Prevenar or a control vaccine (meningococcal conjugate group C vaccine), at 2, 4,
Mere end 40 kg
More than 40 kg
mere end 40 kg*
more than 40 kilograms
mere end 40 mg daglig af enten simvastatin eller lovastatin (til behandling af for højt kolesterol)
more than 40 mg daily of either simvastatin or lovastatin (medicines used to treat high cholesterol)
mere end 40 mg daglig af enten simvastatin eller lovastatin (til behandling af for højt kolesterol) rifampicin (et antibiotikum), phenytoin, carbamazepin og phenobarbital (anvendes til at kontrollere anfald), dexamethason (til behandling af betændelsestilstande og autoimmune tilstande), digoxin (til behandling af hjertesvigt), ciclosporin (anvendes til at nedsætte din krops forsvarssystem), quinidin og diltiazem (til behandling af unormal hjerterytme), betablokkere og verapamil (til behandling af forhøjet blodtryk).
more than 40 mg daily of either simvastatin or lovastatin (medicines used to treat high cholesterol) rifampicin (an antibiotic), phenytoin, carbamazepine and phenobarbital (used to control seizures), dexamethasone (used to treat inflammatory and auto immune conditions), digoxin (used to treat heart failure), cyclosporin (used to lessen your body’s defenses), quinidine and diltiazem (used to treat abnormal heart rhythms), beta blockers and verapamil (used to treat high blood pressure).
Mere end 60 kg
More than 60 kg
mere end 7 dage i løbet af uge 3 og 4 i behandlingen. mere end 2 uger efter den første måned af behandlingen.
more than 7 days during weeks 3 and 4 of treatment. more than 2 weeks after one month of treatment.
Mere end 80% af de tidligere behandlede patienter kan forvente at få bivirkninger; de bivirkninger, der er indberettet mest almindeligt, forekommer sædvanligvis i den første behandlingsuge.
More than 80% of previously treated patients may be expected to experience adverse reactions; the most commonly reported reactions usually occur during the first week of therapy.
Mere end 9.400 patienter blev undersøgt i tre randomiserede kontrollerede kliniske fase III-studier (Einstein DVT, Einstein PE og Einstein Extension), og desuden blev der foretaget en foruddefineret samlet analyse af Einstein DVT og Einstein PE-studierne.
Over 9,400 patients were studied in three randomised controlled phase III clinical studies (Einstein DVT, Einstein PE and Einstein Extension) and additionally a predefined pooled analysis of the Einstein DVT and Einstein PE studies was conducted.
Mere end 99 % af individerne havde responderet på kighostekomponenten i vaccinen, hvilket var defineret som forekomsten af antistoffer hos initialt seronegative individer (dvs. individer med præ-vaccinationstitre < 15 ELU/ml) eller en post-vaccinationstiter der mindst svarer til præ-vaccinations niveauerne hos individer der initialt var seropositive pga. antistoffer fra moderen.
More than 99% of subjects were considered to have responded to the pertussis component of the vaccine, which was defined as the appearance of antibodies in initially seronegative subjects (i.e. subjects with pre-vaccination titres < 15 ELU/ml) or a post-vaccination titre at least equal to pre-vaccination levels in subjects initially seropositive due to maternally- derived antibodies.
Mere end 99 % af individerne havde responderet på kighostekomponenten i vaccinen, hvilket var defineret som forekomsten af antistoffer hos initialt seronegative individer (dvs. individer med præ-vaccinationstitre < 15 ELU/ml) eller en post-vaccinationstiter der mindst svarer til præ-vaccinationsniveauerne hos individer der initialt var seropositive pga. antistoffer fra moderen.
More than 99% of subjects were considered to have responded to the pertussis component of the vaccine , which was defined as the appearance of antibodies in initially seronegative subjects (i.e. subjects with pre-vaccination titres < 15 ELU/ml) or a post-vaccination titre at least equal to pre-vaccination levels in subjects initially seropositive due to maternally- derived antibodies.
mere end en enkelt dosis
more than a single dose of midazolam is
Mere end halvdelen af alle patienter i hver behandlingsgruppe havde tidligere fået ≥ 3 ITP-behandlinger, og 36 % af patienterne var tidligere splenektomererede.
More than half of all patients in each treatment group had ≥ 3 prior ITP therapies and 36% had a prior splenectomy.
Mere end halvdelen af patienterne forblev anfaldsfrie i 12 måneder (hhv.
More than half of the subjects remained seizure free for 12 months (56.6 % and
Mere end én injektion af Elonva i en behandlingscyklus eller for høj Elonva-dosis og/eller (rec)FSH kan øge risikoen for OHSS.
More than one injection of Elonva within one treatment cycle or too high a dose of Elonva and/or (rec)FSH may increase the risk of OHSS.
Mere modtagelig for infektion
More prone to infection
mere mærkbare hjerteslag, brystsmerter
more noticeable heart-beat, chest pain
Mere om depression.
More about depression
Mere specifikke metoder til evaluering og monitorering af hjertefunktion end EKG er måling af venstre ventrikels ejektionsfraktion ved ekkokardiografi eller endnu bedre ved flervejs-angiografi (MUGA).
More specific methods for the evaluation and monitoring of cardiac functions as compared to ECG are a measurement of left ventricular ejection fraction by echocardiography or preferably by Multigated Angiography (MUGA).
Mere udbredt hæmarthrose,
More extensive haemarthrosis,
Mere udbredt hæmartrose,
More extensive haemarthrosis,
Mere udbredte muligvis allergiske reaktioner er set så tidligt som ved første dosis.
More widespread possibly allergic reactions have been observed, as early as with the first dose.
Merial
MERIAL,
Merial Laboratoire Lyon Porte des Alpes Rue de l’Aviation,
Merial Laboratoire Porte des Alpes Rue de l'Aviation
MERIAL Laboratoire Porte des Alpes Rue de l'Aviation
Laboratoire Porte des Alpes Rue de l'Aviation
Merial, 29 avenue Tony Garnier, 69007 Lyon, Frankrig
MERIAL, 29 avenue Tony Garnier, 69007 Lyon, France
Merial, 29 avenue Tony Garnier, F-69007 Lyon, Frankrig
MERIAL, 29 Avenue Tony Garnier, F-69007 Lyon, France
MERIAL, 29 avenue Tony Garnier, FR-69007 Lyon, Frankrig.
MERIAL, 29 avenue Tony Garnier, 69007 Lyon, France.